Cheng Li

Cheng Li, PhD, CFA, currently serves as Director of Biotech Equity Research at Oppenheimer & Co. Inc., focusing on SMID-cap and large-cap biotechs within CNS, liver disease, and oncology since April 2020, having previously held the title of Associate Director in the same department. Prior to this role, Cheng held positions as Senior Associate in Healthcare Investment at MSQ Ventures and Account Coordinator at Russo Partners, LLC. Cheng completed a Ph.D. in Cell and Developmental Biology from Weill Cornell Graduate School of Medical Sciences, where the dissertation centered on TET enzyme requirements in vertebrate development and hematopoiesis under the guidance of Dr. Mary Goll. Additionally, a Master of Science in Health Informatics was earned from the same institution, along with a Bachelor of Applied Science in Applied Biology and Biotechnology from The Hong Kong Polytechnic University.